Safe re-initiation of infliximab in a patient with renal tuberculosis

Clinical and Experimental Rheumatology

Volumn 27, Issue 3, 2009, Pages 534-

  Kemta Lekpa, F ^a   Marini Portugal, A ^a   Lesprit, P ^a   Chevalier, X ^a   Claudepierre, Pascal ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ANKYLOSING SPONDYLITIS; CASE REPORT; DISEASE SEVERITY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY BIOPSY; KIDNEY TUBERCULOSIS; LETTER; LYMPH NODE BIOPSY; MALE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REMISSION; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ANTITUBERCULAR AGENTS; HUMANS; MALE; SPONDYLITIS, ANKYLOSING; TIME FACTORS; TUBERCULOSIS, RENAL; WITHHOLDING TREATMENT;

EID: 67651151462     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (9)

1. MAINI R, ST CLAIR EW, BREEDVELD F et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-1939.
2. BRANDT J, HAIBEL H, CORNELY D et al.: Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor α monoclonal antibody infliximab. Arthritis Rheum 2000; 43: 1346-1352
3. KEANE J, GERSHON S, WISE RP et al.: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Eng J Med 2001; 345: 1098-1104
4. SALMON D: GTI and AFSSAPS. Groupe tuberculose et infliximab. Agence Française de Sécurité Sanitaire de Produits de Santé. Recommendations about the prevention and management of tuberculosis in patients taking infliximab. Joint Bone Spine 2002; 69: 170-172
5. GARCÍA VIDAL C, RODRÍGUEZ FERNÁNDEZ S, MARTÍNEZ LACASA J et al.: Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 2005; 40: 756-759
6. AREND SM, LEYTEN EM, FRANKEN WP, HUISMAN EM, VAN DISSEL JT: A patient with de novo tuberculosis during anti-tumor necrosis factor-alpha therapy illustrating diagnosis pitfalls and paradoxical response to treatment. Clin Infect Dis 2007; 45: 1470-1475
7. MATSUMOTO T, TANAKA T, KAWASE I: Infliximab for rheumatoid arthritis in a patient with tuberculosis. N Engl J Med 2006; 355: 740-741 (Pubitemid 44244562)
8. ASLANIDIS S, PYRPASOPOULOU A, DOUMA S, PETIDIS K: Is it safe to readminister tumor necrosis factor alpha antagonists following tuberculosis flare? Arthritis Rheum 2008; 58: 327-328
9. DENIS B, LEFORT A, FLIPO RM et al.: Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-alpha antagonist therapy: safe re-initiation of TNF-alpha blockers after appropriate anti-tuberculous treatment. Clin Microbiol Infect 2008; 14: 183-186